1. Brenner FW, Villar RG, Angulo FJ, Tauxe R, Swaminathan
B. Salmonella nomenclature. J Clin Microbiol.
2000;38(7):2465-2467.
2. Bopp CA, Brenner FW, Fields PI, Wells JG, Strockbine NA. Escherichia,
Shigella, and Salmonella. In: Murray PR,
Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual
of Clinical Microbiology. 8th ed. Herndon, VA: ASM Press;
2003:654-671.
3.Voetsch AC, Van Gilder TJ, Angulo FJ, et al.
FoodNet estimate of the burden of illness caused by nontyphoidal Salmonella infections
in the United States. Clin Infect Dis. 2004;38(suppl
3):S127-134.
4. Centers for Disease Control and Prevention. Preliminary FoodNet
data on the incidence of infection with pathogens transmitted commonly through
food—10 states, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(14):366-370.
5. Mermin J, Hutwagner L, Vugia D, et al. Reptiles, amphibians,
and human Salmonella infection: a population-based,
case-control study. Clin Infect Dis. 2004;38(suppl
3):S253-261.
6. Angulo FJ, Johnson KR, Tauxe RV, Cohen ML. Origins and consequences
of antimicrobial-resistant nontyphoidal Salmonella:
implications for the use of fluoroquinolones in food animals. Microb
Drug Resist. 2000;6(1):77-83.
7. White DG, Zhao S, Sudler R, et al. The isolation of antibiotic-resistant
Salmonella from
retail ground meats.
N Engl J Med. 2001;345:1147-1154.
[PubMed: 11642230]
8. Blaser MJ, Newman LS. A review of human salmonellosis. Infective
dose. Rev Infect Dis. 1982;4(6 Pt. 1):1096-1106.
9. Buchwald DS, Blaser MJ. A review of human salmonellosis.
Duration of excretion following infection with nontyphi Salmonella. Rev
Infect Dis. 1984;6(3 Pt. 2):345-356.
10. Jones TF, Ingram LA, Fullerton KE, et al. A case-control
study of the epidemiology of sporadic Salmonella infection
in infants. Pediatrics. 2006;118 (6):2380-2387.
11. Goosney DL, Knoechel DG, Finlay BB. Enteropathogenic E.
coli, Salmonella, and Shigella: masters
of host cell cytoskeletal exploitation. Emerg Infect Dis. 1999;5(2):216-223.
12. Guerrant RL, Steiner TS, Lima AA, Bobak DA. How intestinal
bacteria cause disease. J Infect Dis. 1999;179(suppl
2):S331-337.
13. Lee VT, Schneewind O. Type III secretion machines and the
pathogenesis of enteric infections caused by
Yersinia and
Salmonella spp.
Immunol
Rev. 1999;168:241-255.
[PubMed: 10399078]
14. Sansonetti PJ, Phalipon A. M cells as ports of entry for
enteroinvasive pathogens: mechanisms of interaction, consequences
for the disease process. Semin Immunol. 1999;11(3):193-203.
15. Darwin KH, Miller VL. Molecular basis of the interaction
of Salmonella with the intestinal mucosa. Clin
Microbiol Rev. 1999;12(3):405-428.
16. Pavia AT, Shipman LD, Wells JG, et al. Epidemiologic evidence
that prior antimicrobial exposure decreases resistance to infection
by antimicrobial-sensitive Salmonella. J
Infect Dis. 1990;161(2):255-260.
17. Glynn MK, Reddy V, Hutwagner L, et al. Prior antimicrobial
agent use increases the risk of sporadic infections with multidrug-resistant Salmonella
enterica serotype Typhimurium: a FoodNet case-control study,
1996-1997. Clin Infect Dis. 2004;38(suppl 3):S227-236.
18.Levine WC, Buehler JW, Bean NH, Tauxe RV. Epidemiology
of nontyphoidal Salmonella bacteremia during the
human immunodeficiency virus epidemic. J Infect Dis. 1991;164(1):81-87.
19. Sanchez TH, Brooks JT, Sullivan PS, et al. Bacterial diarrhea
in persons with HIV infection, United States, 1992-2002. Clin
Infect Dis. 2005;41(11): 1621-1627.
20. Vugia DJ, Samuel M, Farley MM, et al. Invasive Salmonella infections
in the United States, FoodNet, 1996-1999: incidence, serotype distribution, and
outcome. Clin Infect Dis. 2004;38(suppl 3):S149-156.
21. Weinberger M, Andorn N, Agmon V, Cohen D, Shohat T, Pitlik
SD. Blood invasiveness of Salmonella enterica as
a function of age and serotype. Epidemiol Infect. 2004;132(6):1023-1028.
22. Jones TF, Ingram LA, Cieslak PR, et al. Salmonellosis outcomes
differ substantially by serotype.
J Infect Dis. 2008;198:109-114.
[PubMed: 18462137]
23. Torrey S, Fleisher G, Jaffe D. Incidence of Salmonella bacteremia
in infants with Salmonella gastroenteritis. J
Pediatr. 1986;108(5 Pt 1):718-721.
24. Cohen JI, Bartlett JA, Corey GR. Extra-intestinal manifestations
of salmonella infections. Medicine (Baltimore). 1987;66(5):349-388.
25. Schutze GE, Schutze SE, Kirby RS. Extraintestinal salmonellosis
in a children’s hospital. Pediatr Infect Dis J. 1997;16(5):482-485.
26. Zenilman JM. Typhoid fever. JAMA. 1997;278 (10):847-850.
27. Mermin JH, Townes JM, Gerber M, Dolan N, Mintz ED, Tauxe
RV. Typhoid fever in the United States, 1985–1994: changing
risks of international travel and increasing antimicrobial resistance. Arch
Intern Med. 1998;158(6):633-638.
28. Misra S, Diaz PS, Rowley AH. Characteristics of typhoid
fever in children and adolescents in a major metropolitan area in
the United States. Clin Infect Dis. 1997;24(5):998-1000.
29. Stormon MO, McIntyre PB, Morris J, Fasher B. Typhoid fever
in children: diagnostic and therapeutic difficulties. Pediatr
Infect Dis J. 1997;16 (7):713-714.
30. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet. 2005;366(9487):749-762.
31. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid
fever. N Engl J Med. 2002;347(22): 1770-1782.
32. Nguyen QC, Everest P, Tran TK, et al. A clinical, microbiological,
and pathological study of intestinal perforation associated with
typhoid fever. Clin Infect Dis. 2004;39(1):61-67.
33. Butler T, Islam A, Kabir I, Jones PK. Patterns of morbidity
and mortality in typhoid fever dependent on age and gender: review
of 552 hospitalized patients with diarrhea. Rev Infect Dis. 1991;13(1):85-90.
34. Ferreccio C, Levine MM, Manterola A, et al. Benign bacteremia
caused by Salmonella typhi and paratyphi in
children younger than 2 years. J Pediatr. 1984;104(6):899-901.
35. Crump JA, Kretsinger K, Gay K, et al. Clinical response
and outcome of infection with Salmonella enterica serotype
Typhi with decreased susceptibility to fluoroquinolones: a United
States foodnet multicenter retrospective cohort study. Antimicrob
Agents Chemother. 2008;52(4):1278-1284.
36. Parry CM, Ho VA, Phuong le T, et al. Randomized controlled
comparison of
ofloxacin,
azithromycin, and an ofloxacin-azithromycin combination
for treatment of multidrug-resistant and nalidixic acid-resistant
typhoid fever.
Antimicrob Agents Chemother. 2007;51(3):819-825.
37. Dolecek C, Tran TP, Nguyen NR, et al. A multi-center randomised
controlled trial of
gatifloxacin versus
azithromycin for the treatment
of uncomplicated typhoid fever in children and adults in Vietnam.
PLoS
ONE. 2008;3(5):e2188.
38. Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L. Typhoid
fever vaccines: systematic review and meta-analysis of randomised
controlled trials. Vaccine. 2007;25(45):7848-7857.
39. Guzman CA, Borsutzky S, Griot-Wenk M, et al. Vaccines against
typhoid fever. Vaccine. 2006;24 (18):3804-3811.
40. Shiferaw B, Shallow S, Marcus R, et al. Trends in population-based
active surveillance for shigellosis and demographic variability
in FoodNet sites, 1996-1999. Clin Infect Dis. 2004;38(suppl 3):S175-180.
41. Parsot C, Sansonetti PJ. Invasion and the pathogenesis of
Shigella infections.
Curr
Top Microbiol Immunol. 1996;209:25-42.
[PubMed: 8742244]
42. Sansonetti PJ. The bacterial weaponry: lessons from
Shigella.
Ann
N Y Acad Sci. 2006;1072:307-312.
[PubMed: 17057210]
43. Ashkenazi S. Shigella infections in children:
new insights. Semin Pediatr Infect Dis. 2004;15(4):246-252.
44. Jennison AV, Verma NK. Shigella flexneri infection:
pathogenesis and vaccine development. FEMS Microbiol Rev. 2004;28(1):43-58.
45. Huskins WC, Griffiths JK, Faruque AS, Bennish ML. Shigellosis
in neonates and young infants. J Pediatr. 1994;125(1):14-22.
46. Perles Z, Bar-Ziv J, Granot E. Brain edema: an underdiagnosed
complication of Shigella infection. Pediatr
Infect Dis J. 1995;14(12):1114-1115.
47. Struelens MJ, Patte D, Kabir I, Salam A, Nath SK, Butler
T. Shigella septicemia: prevalence, presentation,
risk factors, and outcome. J Infect Dis. 1985;152(4):784-790.
48. Khan WA, Dhar U, Salam MA, Griffiths JK, Rand W, Bennish
ML. Central nervous system manifestations of childhood shigellosis:
prevalence, risk factors, and outcome. Pediatrics. 1999;103(2):E18.
49. Houdouin V, Doit C, Mariani P, et al. A pediatric cluster
of Shigella dysenteriae serotype 1 diarrhea with
hemolytic uremic syndrome in 2 families from France. Clin
Infect Dis. 2004;38(9):e96-99.
50. Bloom PD, MacPhail AP, Klugman K, Louw M, Raubenheimer C,
Fischer C. Haemolytic-uraemic syndrome in adults with resistant
Shigella
dysenteriae type I.
Lancet. 1994;344(8916):206.
[PubMed: 7912809]
51. Gaston JS. Shigella induced reactive arthritis. Ann
Rheum Dis. 2005;64(4):517-518.
52. Haukka K, Siitonen A. Emerging resistance to newer antimicrobial
agents among Shigella isolated from Finnish foreign
travellers. Epidemiol Infect. 2008;136(4):476-482.
53. Sivapalasingam S, Nelson JM, Joyce K, Hoekstra M, Angulo
FJ, Mintz ED. High prevalence of antimicrobial resistance among Shigella isolates
in the United States tested by the National Antimicrobial Resistance
Monitoring System from 1999 to 2002. Antimicrob Agents Chemother. 2006;50(1):49-54.
54. Jain SK, Gupta A, Glanz B, Dick J, Siberry GK. Antimicrobial-resistant
Shigella
sonnei: limited antimicrobial treatment options for children
and challenges of interpreting in vitro
azithromycin susceptibility.
Pediatr
Infect Dis J. 2005;24(6):494-497.
55. Basualdo W, Arbo A. Randomized comparison of
azithromycin
versus
cefixime for treatment of shigellosis in children.
Pediatr
Infect Dis J. 2003;22(4):374-377.
56. Varsano I, Eidlitz-Marcus T, Nussinovitch M, Elian I. Comparative
efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis
in children. J Pediatr. 1991;118(4 Pt 1):627-632.
57. Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison
of
ciprofloxacin suspension and pivmecillinam for childhood shigellosis.
Lancet. 1998;352(9127):522-527.
58. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment
of shigellosis: V. Comparison of
azithromycin and
ciprofloxacin.
A double-blind, randomized, controlled trial.
Ann Intern Med. 1997;126(9):697-703.
59. Bhattacharya K, Bhattacharya MK, Dutta D, et al. Double-blind,
randomized clinical trial for safety and efficacy of norfloxacin
for shigellosis in children. Acta Paediatr. 1997;86(3):319-320.
60. Nataro JP, Kaper JB. Diarrheagenic Eschericia coli. Clin
Microbiol Rev. 1998;11(1):142-201.
61. Kaper JB, Nataro JP, Mobley HL. Pathogenic Eschericia
coli. Nat Rev Microbiol. 2004;2(2):123-140.
62. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Eschericia
coli in human medicine. Int J Med Microbiol. 2005;295(6-7):405-418.
63. Voetsch AC, Angulo FJ, Rabatsky-Ehr T, et al. Laboratory
practices for stool-specimen culture for bacterial pathogens, including Escherichia coli O157:H7,
in the FoodNet sites, 1995-2000. Clin Infect Dis. 2004;38(suppl
3):S190-197.
64. Brooks JT, Sowers EG, Wells JG, et al. Non-O157 Shiga toxin-producing Escherichia
coli infections in the United States, 1983-2002. J Infect
Dis. 2005;192(8):1422-1429.
65. Aranda KR, Fagundes-Neto U, Scaletsky IC. Evaluation of
multiplex PCRs for diagnosis of infection with diarrheagenic Escherichia
coli and Shigella spp. J Clin
Microbiol. 2004;42(12):5849-5853.
66. Mintz ED. Enterotoxigenic Escherichia coli: outbreak
surveillance and molecular testing. Clin Infect Dis. 2006;42(11):1518-1520.
67. Nataro JP. Enteroaggregative Escherichia coli pathogenesis. Curr
Opin Gastroenterol. 2005;21 (1):4-8.
68. Pereira AL, Ferraz LR, Silva RS, Giugliano LG. Enteroaggregative Escherichia
coli virulence markers: positive association with distinct
clinical characteristics and segregation into 3 enteropathogenic E.
coli serogroups. J Infect Dis. 2007;195(3):366-374.
69. Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL.
Epidemiology of Escherichia coli O157:H7 outbreaks,
United States, 1982-2002. Emerg Infect Dis. 2005;11(4):603-609.
70. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia
coli and haemolytic uraemic syndrome. Lancet. 2005;365(9464):1073-1086.
71. Thorpe CM. Shiga toxin-producing Escherichia coli infection. Clin
Infect Dis. 2004;38(9):1298-1303.
72. Koehler KM, Lasky T, Fein SB, et al. Population-based incidence
of infection with selected bacterial enteric pathogens in children
younger than five years of age, 1996-1998. Pediatr Infect
Dis J. 2006;25(2):129-134.
73. Voetsch AC, Kennedy MH, Keene WE, et al. Risk factors for
sporadic Shiga toxin-producing Escherichia coli O157
infections in FoodNet sites, 1999-2000. Epidemiol Infect. 2007;135(6):993-1000.
74. Kassenborg HD, Hedberg CW, Hoekstra M, et al. Farm visits
and undercooked hamburgers as major risk factors for sporadic Escherichia
coli O157:H7 infection: data from a case-control study
in 5 FoodNet sites. Clin Infect Dis. 2004;38(suppl
3):S271-278.
75. Griffin PM, Tauxe RV. The epidemiology of infections caused
by
Escherichia coli O157:H7, other enterohemorrhagic
E.
coli, and the associated hemolytic uremic syndrome.
Epidemiol Rev. 1991;13:60-98.
[PubMed: 1765120]
76. Beatty ME, Adcock PM, Smith SW, et al. Epidemic diarrhea
due to enterotoxigenic Escherichia coli. Clin
Infect Dis. 2006;42(3):329-334.
77. Daniels NA. Enterotoxigenic Escherichia coli: Traveler’s
diarrhea comes home. Clin Infect Dis. 2006;42(3):335-336.
78. Wanke CA, Mayer H, Weber R, Zbinden R, Watson DA, Acheson
D. Enteroaggregative Escherichia coli as a potential
cause of diarrheal disease in adults infected with human immunodeficiency
virus. J Infect Dis. 1998;178(1):185-190.
79. Nataro JP, Mai V, Johnson J, et al. Diarrheagenic Escherichia
coli infection in Baltimore, Maryland, and New Haven, Connecticut. Clin Infect
Dis. 2006;43(4):402-407.
80. Huang DB, Mohanty A, DuPont HL, Okhuysen PC, Chiang T. A
review of an emerging enteric pathogen: enteroaggregative Escherichia
coli. J Med Microbiol. 2006;55(Pt 10):1303-1311.
81. Nataro JP, Deng Y, Cookson S, et al. Heterogeneity of enteroaggregative Escherichia
coli virulence demonstrated in volunteers. J Infect
Dis. 1995;171(2):465-468.
82. Kimmitt PT, Harwood CR, Barer MR. Induction of type 2 Shiga
toxin synthesis in Escherichia coli O157 by 4-quinolones. Lancet. 1999;353(9164):1588-1589.
83. Kimmitt PT, Harwood CR, Barer MR. Toxin gene expression
by Shiga toxin-producing
Escherichia coli: the
role of antibiotics and the bacterial SOS response.
Emerg
Infect Dis. 2000;6:458-465.
[PubMed: 10998375]
84. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, Acheson
DW. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages,
toxin production, and death in mice. J Infect Dis. 2000;181(2):664-670.
85. Pavia AT, Nichols CR, Green DP, et al. Hemolytic-uremic
syndrome during an outbreak of Escherichia coli O157:H7
infections in institutions for mentally retarded persons: clinical
and epidemiologic observations. J Pediatr. 1990;116(4):544-551.
86. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The
risk of the hemolytic-uremic syndrome after antibiotic treatment
of Escherichia coli O157:H7 infections [see
comments]. N Engl J Med. 2000;342(26):1930-1936.
87. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines
for the management of infectious diarrhea. Clin Infect Dis. 2001;32(3):331-351.
88. Guion CE, Ochoa TJ, Walker CM, Barletta F, Cleary TG. Detection
of diarrheagenic Escherichia coli by use of melting-curve
analysis and real-time multiplex PCR. J Clin Microbiol. 2008;46(5):1752-1757.
89. Infante RM, Ericsson CD, Jiang ZD, et al. Enteroaggregative Escherichia
coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol
Hepatol. 2004;2(2):135-138.
90. Wanke CA, Gerrior J, Blais V, Mayer H, Acheson D. Successful
treatment of diarrheal disease associated with enteroaggregative Escherichia
coli in adults infected with human immunodeficiency virus. J
Infect Dis. 1998;178(5):1369-1372.